Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Drug-induced interstitial lung disease (ILD) is one of the most serious adverse events with a high mortality rate and represents a serious clinical problem. However, gemcitabine plus nab-paclitaxel (GnP)-induced ILD in pancreatic cancer (PC) patients has not been thoroughly investigated. Therefore, we conducted this study to examine the clinical characteristics of GnP-induced ILD and identify risk factors for developing ILD.

Methods

We retrospectively investigated consecutive patients with PC who received GnP between January 2015 and April 2020. We compared the clinical characteristics and overall survival (OS) according to ILD occurrence and explored risk factors including ABO blood type for developing ILD.

Results

Of the 910 patients included in this study, ILD occurred in 20 patients (2.2%). PC patients who developed ILD had a significantly higher frequency of blood type B compared to those without ILD (42% vs. 22%, p ˂ 0.05). Other baseline characteristics including smoking history and current/previous lung disease were not different between the two groups. Median time from initiation of GnP to onset of ILD was 80 days. All patients recovered from ILD and OS was not significantly different according to ILD occurrence. Multivariate analysis revealed that blood type B was an independent risk factor for developing ILD.

Conclusions

We demonstrated that GnP-induced ILD occurred in 2.2% of PC patients with no mortality and OS did not differ according to ILD occurrence. Furthermore, we clarified that ABO blood type B was an independent risk factor for developing ILD in PC patients receiving GnP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

PC:

Pancreatic cancer

GnP:

Gemcitabine plus nab-paclitaxel

ECOG:

Eastern Cooperative Oncology Group

PS:

Performance status

ILD:

Interstitial lung disease

COPD:

Chronic obstructive pulmonary disease

OS:

Overall survival

TTF:

Time to treatment failure

OR:

Odds ratio

CI:

Confidence interval

References

  1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30

    Article  Google Scholar 

  2. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Article  Google Scholar 

  3. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

    Article  CAS  Google Scholar 

  4. Barenboim A, Lahat G, Geva R et al (2018) Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 44(10):1619–1623

    Article  Google Scholar 

  5. Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264(3):457–463

    Article  Google Scholar 

  6. Ielpo B, Duran H, Diaz E et al (2016) Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol 42(9):1394–1400

    Article  CAS  Google Scholar 

  7. Philip PA, Lacy J, Portales F et al (2020) Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5(3):285–294

    Article  Google Scholar 

  8. Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801–810

    Article  CAS  Google Scholar 

  9. Hamada T, Yasunaga H, Nakai Y et al (2016) Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology 21(2):338–343

    Article  Google Scholar 

  10. Furuse J, Gemma A, Ichikawa W et al (2017) Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 47(9):832–839

    Article  Google Scholar 

  11. Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105(12):1584–1590

    Article  CAS  Google Scholar 

  12. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966

    Article  CAS  Google Scholar 

  13. Okusaka T, Furuse J, Funakoshi A et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102(2):425–431

    Article  CAS  Google Scholar 

  14. Nishimura M, Toyoda M, Takenaka K et al (2016) The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 77(6):1165–1170

    Article  CAS  Google Scholar 

  15. Udagawa C, Horinouchi H, Shiraishi K et al (2019) Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS ONE 14(10):e0223371

    Article  CAS  Google Scholar 

  16. Li Y, Liu L, Huang Y et al (2020) Association of ABO polymorphisms and pancreatic cancer/cardiocerebrovascular disease: a meta-analysis. BMC Med Genet 21(1):41

    Article  CAS  Google Scholar 

  17. Xu HL, Cheng JR, Zhang W et al (2014) Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population. Chin J Cancer 33(2):68–73

    Article  CAS  Google Scholar 

  18. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458

    Article  CAS  Google Scholar 

  19. Ioka T, Katayama K, Tanaka S et al (2013) Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan. Jpn J Clin Oncol 43(2):139–145

    Article  Google Scholar 

  20. Ogawa Y, Suzuki E, Mikata R et al (2018) Five cases of interstitial pneumonitis due to gemcitabine and nab-paclitaxel combination treatment in pancreatic cancer patients. Pancreas 47(7):e42–e43

    Article  Google Scholar 

  21. Irie H, Suzuki R, Takagi T et al (2020) Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis. Cancer Chemother Pharmacol 85(3):517–523

    Article  CAS  Google Scholar 

  22. Kashiwada T, Saito Y, Terasaki Y et al (2019) Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. Jpn J Clin Oncol 49(2):165–173

    Article  Google Scholar 

  23. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41(9):986–990

    Article  CAS  Google Scholar 

  24. Li SS, Zhou CY, Liao R et al (2020) ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 99(14):e19413

    Article  CAS  Google Scholar 

  25. Zhang BL, He N, Huang YB et al (2014) ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 15(11):4643–4650

    Article  Google Scholar 

  26. Duan YF, Zhu F, Li XD et al (2015) Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis. Tumour Biol 36(7):5081–5087

    Article  CAS  Google Scholar 

  27. Melzer D, Perry JR, Hernandez D et al (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4(5):e1000072

    Article  Google Scholar 

  28. Paré G, Chasman DI, Kellogg M et al (2008) Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 4(7):e1000118

    Article  Google Scholar 

  29. Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19(9):1863–1872

    Article  CAS  Google Scholar 

  30. Qi L, Cornelis MC, Kraft P et al (2010) Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 19(9):1856–1862

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We have no funds and grants in this study.

Author information

Authors and Affiliations

  1. Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan

    Tsuyoshi Takeda, Takashi Sasaki, Koshiro Fukuda, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka & Naoki Sasahira

Authors
  1. Tsuyoshi Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koshiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takafumi Mie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takaaki Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuto Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiyoshi Kasuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masato Matsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masato Ozaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoki Sasahira
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study Concept and Design: TT, TS, NS. Acquisition of Data: all authors. Analysis and interpretation of data: TT, TS, NS. Drafting of the article: TT. Critical revision of the article for important intellectual content: all authors. Final approval of the article: all authors.

Corresponding author

Correspondence to Takashi Sasaki.

Ethics declarations

Conflict of interest

All authors declare no conflicts of interests for this article. Conflicts of interests outside this work are as follows; Naoki Sasahira received research funding from Zeria, Eisai, Kyowa Hakko Kirin, Baxalta and Taiho Pharmaceutical. Masato Ozaka received honoraria from Taiho Pharmaceutical, Yakult, Bayer, Pfizer, Novartis, Takeda Pharmaceutical Company Limited, Eisai, EA pharma and Mitsubishi Tanabe Pharma Corporation and research funding from Merck & Co., Inc., Incyte, ASLAN Pharmaceuticals, Taiho Pharmaceutical and Yakult. Takashi Sasaki received honoraria from Taiho Pharmaceutical and Eisai.

Ethics approval

This study was approved by the ethics committee of our institution (Institutional Review Board number: 2020-1041).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeda, T., Sasaki, T., Fukuda, K. et al. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Int J Clin Oncol 26, 543–551 (2021). https://doi.org/10.1007/s10147-020-01827-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01827-2

Keywords

Search

Navigation